Talis Biomedical (TLIS) Stock Price

Talis Biomedical Price

NASDAQ·CLOSED
2.84
​
Market closed

Revenue at Talis Biomedical has contracted by 2.2% per year over the past 5 years to 2.13 M USD. For Talis Biomedical, the net margin of -2,905.7% is down versus 663.4% a few years ago. The consensus 12-month price target for Talis Biomedical is 5.10 USD, about 79.6% above where the stock trades today. Of 6 analysts, 0 rate the stock a buy — an overall Sell consensus.

Talis Biomedical stock price

Access this data via the Eulerpool API

Talis Biomedical business model & stock analysis

Talis Biomedical Corp is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Redwood City, California and currently employs 102 full-time employees. The company went IPO on 2021-02-12. Talis Biomedical Corporation is engaged in transforming diagnostic testing by developing and commercializing products that are designed to enable molecular testing for infectious diseases and other conditions at the point of care. The firm is engaged in developing the Talis One system, a cloud-enabled molecular diagnostic platform. The Talis One system consists of compact instrument, single-use test cartridges and software that is designed to support a central cloud database, which work together and are designed to provide central laboratory levels of accuracy and be operated by an untrained user. The company is also focused on developing Talis One assay kits for respiratory infections, and infections related to women's health and sexually transmitted infections (STIs). The company is also developing influenza A and influenza B tests to be included as part of a respiratory panel with its COVID-19 assay (Respiratory Panel), as well as exploring adding a respiratory syncytial virus (RSV) test.

Frequently asked questions about Talis Biomedical

Analysts currently set an average price target of 5.10 USD for the Talis Biomedical stock (median: 5.10 USD), implying +79.6 % versus the latest price. The consensus is based on 6 analyst ratings.

6 analysts currently rate the Talis Biomedical stock: 0 recommend buying, 2 holding and 4 selling.

Converted at the current exchange rate, the Talis Biomedical share trades at 2.54 EUR (2.84 USD).

The Talis Biomedical share (TLIS) is listed on 1 stock exchanges, including: NASDAQ (TLIS).

The revenue cannot currently be calculated for Talis Biomedical.

The profit cannot currently be calculated for Talis Biomedical.

The P/E ratio cannot be calculated for Talis Biomedical at the moment.

The P/S cannot be calculated for Talis Biomedical currently.

The Eulerpool Quality Score for Talis Biomedical is 2/10.

The ISIN of Talis Biomedical is US87424L2079. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Talis Biomedical is TLIS. The ticker symbol is used to trade Talis Biomedical shares on the stock exchange.

Fair ValueTerminal
2.61 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Equipment & Supplies
Number of shares
Employees
Revenue per Employee
20,921.57 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website talisbio.com
Currency
USD
Initial public offering
Feb 12, 2021
ISIN
US87424L2079
Cusip
87424L207
Market capitalization
5.17 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2024
-0.12
P/Ee 2025
-0.10
P/S
P/Se
—
EV/EBIT
1.12
P/B Ratio
0.07
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-89.71 %
Last updated Oct 14, 2026, 5:58 PM

Talis Biomedical Peer Group

Talis Biomedical Ticker

NASDAQ · TLIS

Talis Biomedical FIGI

TLIS:US · BBG00Y9D99K6TLIS:UA · BBG00Z0Z98F1TLIS:UC · BBG00Z0Z98G0TLIS:UN · BBG00Z0Z98J7TLIS:UP · BBG00Z0Z98K5TLIS:UB · BBG00Z0Z98M3TLIS:UM · BBG00Z0Z98P0TLIS:UX · BBG00Z0Z98Q9TLIS:UR · BBG00Z0Z98R8TLIS:UD · BBG00Z0Z98W2TLIS:UF · BBG00Z0Z98Z9TLIS:VY · BBG00Z0Z9905

All fundamentals and in-depth analysis of Talis Biomedical

Our stock analysis for Talis Biomedical stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Talis Biomedical. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.